Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

Daewoong-Bersiporocin

More Like This

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

PR Newswire associated0

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

PR Newswire associated0

Orphalan becomes the first European company to enter in China's Wilson Disease market

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

Novotech Identifies Strategic Opportunities in Idiopathic Pulmonary Fibrosis Trials with Release of Global Market Insights